Ardelyx Inc. | Mutual Funds
Mutual Funds that own Ardelyx Inc.
Vanguard Total Stock Market Index Fund
1,154,946
1.86%
0
0%
07/31/2018
JPMorgan Small Cap Value Fund
746,200
1.2%
450,500
0.16%
07/31/2018
iShares Russell 2000 ETF
696,460
1.12%
-372
0.01%
09/06/2018
iShares Nasdaq Biotechnology ETF
693,998
1.12%
-9,072
0.03%
09/06/2018
Appleseed Fund
669,591
1.08%
669,591
1.59%
07/31/2018
Vanguard Extended Market Index Fund
492,219
0.79%
4,200
0%
07/31/2018
Tekla Life Sciences Investors
320,135
0.52%
0
0.28%
12/31/2017
319,235
0.51%
0
0.2%
03/31/2018
Columbia Small Cap Value Fund I
312,440
0.5%
89,620
0.2%
05/31/2018
iShares Russell 2000 Value ETF
312,214
0.5%
0
0.01%
09/06/2018
| Address |
34175 Ardenwood Boulevard
Fremont California 94555
United States
|
|
Employees
|
- |
| Website |
http://www.ardelyx.com |
| Updated |
07/08/2019 |
| Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicine for the treatment of renal diseases. It also focuses on the development of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. |
